93 results on '"Lamberti G"'
Search Results
2. MA18.09 Carboplatin, Etoposide, Bevacizumab, and Atezolizumab in Patients with Extensive-Stage SCLC - GOIRC-01-2019 CeLEBrATE Trial
3. OA19.05 Activating MET Tyrosine Kinase Domain Mutations as de Novo Oncogenic Drivers in Non-small Cell Lung Cancer
4. P2.07-03 Factors Associated with Disease Progression after Discontinuation of Immunotherapy for Immune-Related Toxicity in Non-small Cell Lung Cancer
5. MA20.06 Association of TTF-1 Expression with Outcomes to Immunotherapy and KRAS G12C Inhibition in Lung Adenocarcinoma
6. Uncertainty Quantification for RANS Predictions of Wind Loads on Buildings
7. Calculating wind loading using CFD
8. Comparison of High-Resolution Pressure Peaks in Closed and Open-Section Wind Tunnels
9. MP71-14 SURGICAL TIMING IN PATIENTS WITH RETENTION/DYSURIA AFTER MID-URETHRAL SLING: A MODIFIED DELPHI CONSENSUS
10. Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma
11. 14 Effect of breed on oocyte recovery and embryo production following ovum pickup and fertility outcomes after transferring fresh
12. A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions
13. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer
14. MA01.08 Impact of [18F]FDG PET/CT-derived Metabolic Parameters on Outcomes in Extensive-stage SCLC
15. MA02.09 Impact of Baseline Clinicopathologic and Genomic Features on Outcomes to KRAS G12C Inhibitors in Patients with NSCLC
16. 1060P Impact of baseline clinicopathologic and genomic features on outcomes to KRAS G12C inhibitors in patients with NSCLC
17. EP14.01-006 CeLEBrATE: Phase II trial of CarbopLatin, Etoposide, Bevacizumab and Atezolizumab in Patients with exTEnsive-Stage SCLC-GOIRC-01-2019
18. P1.15-03 Clinical Outcomes Among Patients with Non-small Cell Lung Cancer Who Discontinued Immune Checkpoint Inhibitors Due to Toxicity
19. EP08.01-043 Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced Non-small Cell Lung Cancer (NSCLC)
20. T.05.5 ANTIPROLIFERATIVE ACTIVITY OF HIGH DOSE SOMATOSTATIN ANALOGS IN GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE TUMORS: A SYSTEMATIC REVIEW AND META-ANALYSIS
21. 149P Total metabolic tumor volume: A new potential prognostic factor in SCLC
22. Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy
23. AF.108 ROLE OF FDG PET IN THE MANAGEMENT OF GRADE 1 GASTROENTERO-PANCREATIC NEUROENDOCRINE NEOPLASIA
24. Treatment of advanced gastro-entero-pancreatic neuro-endocrine tumors: A systematic review and network meta-analysis of phase III randomized controlled trials
25. Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study
26. P33.04 Programmed Death-Ligand 1 (PD-L1) Changes in Non-Small-Cell Lung Cancer (NSCLC): Clinical, Pathologic, and Genomic Correlates
27. P14.26 Diminished Efficacy of PD-(L)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma is Impacted by KRAS Mutation Status
28. PCN168 Lutetium (177LU) Oxodotreotide Versus Standard of Care in Adult Patients with Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETS): A Cost-Consequences Analysis from an Italian Hospital Perspective
29. T03.01.15 SECOND PRIMARY NEOPLASMS IN PATIENTS WITH GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE NEOPLASMS (GEP-NEN): DATA FROM A RETROSPECTIVE IT.A.NET STUDY
30. 1088P Efficacy of post-operative radiation therapy in non-metastatic Merkel cell carcinoma: A registry-based analysis
31. 1179P Therapeutic sequences in advanced grade 1-2 pancreatic neuroendocriene tumours (pNET)
32. 1169P First-line fluoropyrimidine and oxaliplatin chemotherapy in gastro-entero-pancreatic grade 3 well-differentiated neuroendocrine tumours (NET G3)
33. Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer
34. Engineering approaches for drug delivery systems production and characterization
35. Safety of high doses of somatostatin analogs in well differentiated NENs in elderly
36. P2.04-32 Comparison of Clinicopathological and Genomic Characteristics Between NSCLCs with a PD-L1 Tumor Proportion Score of ≥90% vs <1%
37. OA03.07 Immune-Related Adverse Events and Clinical Outcome to Anti PD-1 Axis Inhibition in SCLC: A Multicenter Retrospective Analysis
38. MA09.11 Mechanisms of Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14 Mutant Non-Small Cell Lung Cancer
39. The functioning side of the pancreas: a review on insulinomas
40. Clinical significance of ROS1 5’ deletions detected by FISH and response to crizotinib
41. P.01.15 TUMOUR TYPE AND SIZE ARE PROGNOSTIC FACTORS IN GASTRIC NEUROENDOCRINE NEOPLASIA: A MULTICENTRE RETROSPECTIVE STUDY
42. Multi-centric longitudinal study on electrophysiological diagnostic and prognostic markers in prolonged disorders of consciousness
43. Hydrogels: experimental characterization and mathematical modelling of their mechanical and diffusive behaviour
44. Modeling the modified drug release from curved shape drug delivery systems – Dome Matrix®
45. HPMC-based granules for prolonged release of phytostrengtheners in agriculture
46. Clinical and cost effectiveness of nutritional treatment of a sacral decubitus ulcer in Arnold-Chiari II syndrome
47. PoroViscoElastic model to describe hydrogels' behavior
48. P.05.4: Cancer Progression Control in Inflammatory Bowel Disease: Cyclin D1 and E2F1 Sirna Delivery by New Vectors
49. P103 Evaluation of efficacy of new vectors for siRNA CYCLIN D1 and E2F1 delivery in control of cancer progression in inflammatory bowel disease
50. On the design of tailored liposomes for KRX29 peptide delivery
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.